Humacyte, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Humacyte, Inc. (HUMA) had Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $3.90 million as of 2021-08-26, per its 10-K filed 2023-03-24.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2023-03-24
- 2021-08-26: Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $3.90M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs |
|---|---|
| 2021-08-26 | $3.90M 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |